Publicis Health Media invests for the future and the White House links Tylenol to autism

Medical marketing is faced with gale-force winds of uncertainty, so we’re going to spend most of this week’s episode focused on the industry’s future but in two distinct ways.

For our feature interview, we’re joined by recurring guest Andrea Palmer, the CEO of Publicis Health Media, as well as Brad Liebow, who recently jumped from Spark Foundry to become PHM’s first chief investment officer.

The pair explain why the position was established, how it is designed to further differentiate PHM from other medical marketing agencies and how they assess the modern health media landscape.

After that is our Trends segment, where we’ll discuss the Trump administration’s press conference tying the usage of Tylenol among pregnant women to the rise in cases of autism.

The announcement, while widely-expected, was presented to the American people without solid evidence – so we’ll dive into what it all means for health brands like Tylenol manufacturer Kenvue as well as medical marketers and HCPs.

We’ll also do a bit of housecleaning on those Untitled Letters from the FDA as part of the ongoing DTC pharma ad crackdown. 

Music: “Deep Reflection” by DP and Triple Scoop Music.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: Opal 99 - Can't Go Out and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.